What are the causes of hepatic iron overload and what are the treatment options?

Iron Deposits in the Liver: Causes and Treatment

For hereditary hemochromatosis with iron overload, initiate weekly therapeutic phlebotomy targeting a serum ferritin of 50-100 µg/L, which is the gold standard treatment that prevents end-organ damage and normalizes life expectancy when started before cirrhosis develops. 1

Causes of Hepatic Iron Overload

Iron accumulation in the liver occurs through two primary mechanisms:

Primary (Hereditary) Causes

• Hereditary Hemochromatosis (HH): Most commonly caused by HFE gene mutations, particularly C282Y homozygosity 1, 2
• Non-HFE hemochromatosis: Includes ferroportin mutations and other rare genetic variants 2
• These conditions cause excessive intestinal iron absorption due to dysregulated hepcidin production 3

Secondary Causes

• Transfusion-related iron overload: Each unit of packed red blood cells contains 200-250 mg of elemental iron with no active excretion mechanism 4
• Iron-loading anemias: Thalassemia, sickle cell disease, myelodysplastic syndromes with ineffective erythropoiesis 1, 5
• Chronic liver diseases: Hepatitis C, non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease 1
• Excessive dietary iron intake: African iron overload from traditional beer consumption 4
• Porphyria cutanea tarda 1

Treatment Algorithm

For Hereditary Hemochromatosis

Induction Phase:

• Perform phlebotomy of 500 mL blood weekly or biweekly as tolerated 1
• Check hematocrit/hemoglobin before each phlebotomy; allow no more than 20% decrease from prior level 1
• Monitor serum ferritin every 10-12 phlebotomies 1
• Stop frequent phlebotomy when ferritin reaches 50-100 µg/L 1

Maintenance Phase:

• Continue phlebotomy at intervals to maintain ferritin between 50-100 µg/L 1
• Monitor for iron reaccumulation lifelong 1

Critical Point: Treatment before cirrhosis develops results in normal life expectancy, whereas cirrhotic patients remain at 30% risk of hepatocellular carcinoma and 20% risk of other cirrhotic complications even after adequate iron removal 6. This makes early intervention paramount for mortality reduction.

For Secondary Iron Overload

When phlebotomy is feasible (porphyria cutanea tarda, post-bone marrow transplant, some NAFLD cases):

• Use the same phlebotomy protocol as hereditary hemochromatosis 1
• In NAFLD, phlebotomy improves insulin resistance parameters and reduces ALT levels 1
• Do NOT use phlebotomy for mild secondary iron overload in hepatitis C (hepatic iron concentration <2500 µg/g dry weight) 1

When phlebotomy is contraindicated (ineffective erythropoiesis, transfusion-dependent anemias):

• Deferoxamine (Desferal): 20-40 mg/kg/day via continuous subcutaneous infusion for 8-12 hours nightly, 5-7 nights per week 1
• Deferasirox (Exjade): Oral iron chelator, FDA-approved for secondary iron overload due to ineffective erythropoiesis 1
  • Caution: Not approved for hereditary hemochromatosis; avoid in advanced liver disease; monitor for gastrointestinal side effects and renal impairment 2, 7
• Deferiprone: Alternative oral chelator, particularly useful for cardiac iron overload but carries risk of neutropenia 7

Essential Management Principles

Dietary modifications:

• Avoid vitamin C supplements - accelerates iron mobilization and may saturate transferrin, increasing oxidative stress 1, 6, 1
• Limit red meat consumption 2
• Restrict alcohol intake during iron depletion; patients with cirrhosis must abstain completely 2
• Avoid iron supplements and iron-fortified foods 2
• Avoid raw or undercooked shellfish - risk of fatal Vibrio vulnificus infection in iron-overloaded patients 1, 2

Monitoring requirements:

• Patients with cirrhosis require lifelong hepatocellular carcinoma surveillance every 6 months with ultrasound ± alpha-fetoprotein 2
• Consider liver biopsy when ferritin >1000 µg/L with elevated ALT/AST to assess fibrosis stage 1
• Use elastography to identify advanced fibrosis non-invasively 2, 7

Common Pitfalls to Avoid

1. Do not delay treatment in asymptomatic C282Y homozygotes with elevated ferritin - prophylactic phlebotomy prevents irreversible organ damage 1
2. Do not perform liver biopsy in C282Y homozygotes with ferritin <1000 µg/L and normal liver enzymes - proceed directly to phlebotomy 1
3. Do not use deferasirox in hereditary hemochromatosis - recent safety concerns and lack of approval for this indication 1, 2
4. Do not expect reversal of established cirrhosis - advanced fibrosis is not reversed by iron removal, making early treatment critical 1

Special Considerations

Liver transplantation: Reserved for decompensated cirrhosis; survival now comparable to other indications when adequate iron removal occurs pre-transplant 1

Pregnancy: Iron depletion should avoid iron deficiency; phlebotomy can be paused during pregnancy in mild-moderate cases without advanced liver disease 2